CS MEDICA A/S ("CS MEDICA" or "The Company"), a global MedTech company specializing in CBD and pain management, is pleased to announce a significant achievement in its Global expansion. After rigorous scrutiny, the Indian State's FDA has granted approval for two cosmetic products with CBD from CS MEDICA, the CANNASEN[®] Anti-Hair Loss Serum and CANNASEN[®] PSOR+Atopic Lotion.

Kamlesh Vora, Managing Director at Cannordic India Pvt Ltd, states

"Securing Indian FDA approval for these cosmetic products is just the beginning of our journey in India. We're poised to introduce CS MEDICA's medical innovations, set to redefine the industry, pioneer innovation, and enhance well-being throughout India."

Market Highlights:
The hair loss market in India, with a market size of over 10,000 crore INR (approximately 12 billion DKK), represents a substantial segment where individuals seek effective solutions to combat various types of hair loss, from hereditary to stress-related hair loss.

In the skin atopic lotion market, India boasts a market size of more than 5,000 crore INR (around 6 billion DKK). This market caters to consumers actively seeking dermatologist-recommended products, especially those designed to alleviate conditions like psoriasis, dry, and atopic skin.

Product Highlights:
CANNASEN® Anti-Hair Loss Serum
CANNASEN® Anti-Hair Loss Serum offers a comprehensive and natural solution for those battling hair loss. This clinically tested hair serum features patented ingredients, including Redensyl®, Capixyl®, and CBD (cannabidiol). It is designed to address various types of hair loss, promoting stronger hair growth and thicker strands, while enhancing scalp health.

CANNASEN® PSOR+Atopic Lotion
CANNASEN® PSOR+Atopic Lotion is a moisturizing and natural solution, specifically formulated for daily care of psoriasis, dry skin, and atopic skin. It effectively reduces itching, soothes tight skin, and diminishes redness while improving overall skin texture.